Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Dr. Volker Gerdts says the University of Saskatchewan's Vaccine and Infectious Disease Organization has received permission from the Public Health Agency of Canada to start working on a vaccine.

/The Canadian Press

Dr. Volker Gerdts estimates there are upwards of 200 ferrets at his vaccine research facility in Saskatoon right now, including a shipment of more than 100 recent arrivals. Not to mention dozens of hamsters.

“It’s getting crowded,” Dr. Gerdts says of the lab, one of the largest research centres in Canada. “But that’s what we’re built for.”

Because ferrets’ respiratory systems are similar to humans’, they are now at the leading edge of Canada’s search for a coronavirus vaccine. And the VIDO-InterVac facility at the University of Saskatchewan is at the centre of a global effort to find a solution to the pandemic.

Story continues below advertisement

Dr. Gerdts’s team is one of about 50 international groups working with the World Health Organization, comparing notes and divvying up tasks to see what approach will yield the best shot at a successful vaccine.

Once a week, he and others join a 5 a.m. conference call to share data with researchers around the globe. It is one of the largest co-ordinated efforts the vaccine world has ever seen.

Although researchers are racing flat-out, it is also a frustratingly slow process. Even at an accelerated pace, vaccines take a year or more to develop and mass produce. Most estimates suggest it will be 12 to 18 months before any COVID-19 vaccine is safe for human use.

In an effort to speed things up, though, labs have started to get creative.

WHO’s early coronavirus response raises awkward questions about Beijing relationship

https://www.theglobeandmail.com/canada/article-coronavirus-rules-by-province-physical-distancing-open-closed/

In the case of Dr. Gerdts’s team, that means multitasking – which is where the hamsters come in.

After infecting one group of ferrets with the virus, the lab created an animal model of a potential vaccine, which it has since administered to a second group of healthy ferrets.

The healthy ferrets will soon get a booster shot of the vaccine and, a few weeks later, will be exposed to the virus. In May, the researchers will know whether the vaccine passes its first big test – whether the inoculated ferrets are protected from COVID-19.

Story continues below advertisement

To speed up the process, the lab began the same research on hamsters this week, hoping to get a head start on proving the vaccine works in a second animal, before fully knowing whether it is successful on the ferrets.

Because vaccines must be proven safe in animals before human trials can be attempted, it’s a painstaking process.

“There’s some suggestion out there that hamsters may also be a good model for this disease. So that will allow us to enhance our capacity and get more work done,” Dr. Gerdts said.

Figuring out whether the ferrets have contracted COVID-19 isn’t simple. Unlike humans, ferrets don’t exhibit the outward symptoms of coronavirus that humans might – such as a dry cough. So researchers must examine the ferrets’ lungs postmortem, searching for the telltale lesions that inflict people when the disease invades the respiratory system.

“If the vaccine provides protection, it is a reduction in viral shedding, which is really what is happening between humans when we transmit the virus to each other,” Dr. Gerdts said. “So the less we can transmit the better. That’s what we want a vaccine to do.”

With a massive scientific effort under way, animals such as ferrets and monkeys bred specifically for lab research have been in high demand, prompting concerns among researchers they could soon be in short supply. China – one of the world’s largest suppliers of research monkeys – has restricted animal exports amid the pandemic, leaving some international labs scrambling for suppliers. However, Dr. Volker said those issues haven’t affected the Canadian lab.

Story continues below advertisement

VIDO-InterVac, which is short for the Vaccine and Infectious Disease Organization - International Vaccine Centre, is one of Canada’s largest pandemic-preparedness facilities. The lab received an injection of $12-million from Ottawa last month to buy research equipment and expand its production capacity.

Eventually, VIDO-InterVac will house a manufacturing facility that could make up to 20 million doses of a new vaccine in a pandemic, Dr. Gerdts said. But it will be at least a year or more before construction would be completed, meaning that even if the COVID-19 vaccine is discovered in Canada, most of the country’s doses must still be purchased through contracts the government negotiates with international suppliers.

“If we can really fast-track the regulatory approval for this, we might be able to start producing our own vaccine here in this facility," he said. "But we don’t know that for sure. It’s all unknown at the moment.”

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters.

Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

In the interests of public health and safety, our coronavirus news articles are free for anyone to access. However, The Globe depends on subscription revenue to support our journalism. If you are able, please subscribe to globeandmail.com. If you are already a subscriber, thank you for your support.

Your subscription helps The Globe and Mail provide readers with critical news at a critical time. Thank you for your continued support. We also hope you will share important coronavirus news articles with your friends and family. In the interest of public health and safety, all our coronavirus news articles are free for anyone to access.

Follow related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies